000303495 001__ 303495
000303495 005__ 20250815114532.0
000303495 0247_ $$2doi$$a10.3390/diagnostics15151964
000303495 0247_ $$2pmid$$apmid:40804928
000303495 037__ $$aDKFZ-2025-01686
000303495 041__ $$aEnglish
000303495 082__ $$a610
000303495 1001_ $$00000-0002-3273-8435$$aSchmitz, Daniel$$b0
000303495 245__ $$aDifferentiating Main-Duct IPMN from Chronic Pancreatitis Using Next-Generation Sequencing of Main Pancreatic Duct Fluid: A Pilot Study.
000303495 260__ $$aBasel$$bMDPI$$c2025
000303495 3367_ $$2DRIVER$$aarticle
000303495 3367_ $$2DataCite$$aOutput Types/Journal article
000303495 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1755242064_8667
000303495 3367_ $$2BibTeX$$aARTICLE
000303495 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303495 3367_ $$00$$2EndNote$$aJournal Article
000303495 520__ $$aBackground: A dilated main pancreatic duct (MPD) ≥ 5 mm can be observed in main-duct IPMNs (MD-IPMN) and chronic pancreatitis (CP); however, distinguishing between the two differently treated diseases can be difficult. Cell-free (cf) DNA in MPD fluid obtained by EUS-guided FNA might help to distinguish MD-IPMN from CP. Methods: All patients with a dilated MPD ≥ 5 mm on EUS during the period of 1 June 2017 to 30 April 2024 were prospectively analysed in this single-centre study, with EUS-guided MPD fluid aspiration performed for suspected MD-IPMN or CP in patients who were suitable for surgery. Twenty-two known gastrointestinal cancer genes, including GNAS and KRAS, were analysed by deep targeted (dt) NGS. The results were correlated with resected tissue, biopsy, and long-term follow-up. Results: A total of 164 patients with a dilated MPD were identified, of which 30 (18.3%) underwent EUS-guided FNA, with 1 patient having a minor complication (3.3%). Twenty-two patients (mean MPD diameter of 12.4 (7-31) mm) with a definitive, mostly surgically confirmed diagnosis were included in the analysis. Only a fish-mouth papilla, which was present in 3 of 12 (25%) MD-IPMNs, could reliably differentiate between the two diseases, with history, symptoms, diffuse or segmental MPD dilation, presence of calcifications on imaging, cytology, and CEA in the ductal fluid failing to achieve differentiation. However, GNAS mutations were found exclusively in 11 of the 12 (91.6%) patients with MD-IPMN (p < 0.01), whereas KRAS mutations were identified in both diseases. Conclusions: GNAS testing by dtNGS in aspirated fluid from dilated MPD obtained by EUS-guided FNA may help differentiate MD-IPMN from CP for surgical resection.
000303495 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000303495 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303495 650_7 $$2Other$$achronic
000303495 650_7 $$2Other$$aendoscopic ultrasound-guided fine needle aspiration
000303495 650_7 $$2Other$$ahigh-throughput nucleotide sequencing
000303495 650_7 $$2Other$$aintraductal papillary mucinous neoplasm
000303495 650_7 $$2Other$$apancreatitis
000303495 650_7 $$2Other$$aprospective study
000303495 7001_ $$aPrax, Stefan$$b1
000303495 7001_ $$aKliment, Martin$$b2
000303495 7001_ $$aGocke, Felix$$b3
000303495 7001_ $$aKazdal, Daniel$$b4
000303495 7001_ $$00000-0003-4518-7887$$aAllgäuer, Michael$$b5
000303495 7001_ $$aPenzel, Roland$$b6
000303495 7001_ $$aKirchner, Martina$$b7
000303495 7001_ $$00000-0003-2684-9187$$aNeumann, Olaf$$b8
000303495 7001_ $$0P:(DE-He78)7483734fd8ab316391aa604c95f0e98a$$aSültmann, Holger$$b9$$udkfz
000303495 7001_ $$aBudczies, Jan$$b10
000303495 7001_ $$0P:(DE-He78)95cce409faf956f2db2a954a59d70ec7$$aSchirmacher, Peter$$b11
000303495 7001_ $$aBergmann, Frank$$b12
000303495 7001_ $$aRitz, Jörg-Peter$$b13
000303495 7001_ $$aHinze, Raoul$$b14
000303495 7001_ $$aGrassmann, Felix$$b15
000303495 7001_ $$aRudi, Jochen$$b16
000303495 7001_ $$aStenzinger, Albrecht$$b17
000303495 7001_ $$00000-0002-1036-5391$$aVolckmar, Anna-Lena$$b18
000303495 773__ $$0PERI:(DE-600)2662336-5$$a10.3390/diagnostics15151964$$gVol. 15, no. 15, p. 1964 -$$n15$$p1964$$tDiagnostics$$v15$$x2075-4418$$y2025
000303495 909CO $$ooai:inrepo02.dkfz.de:303495$$pVDB
000303495 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7483734fd8ab316391aa604c95f0e98a$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000303495 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)95cce409faf956f2db2a954a59d70ec7$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000303495 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000303495 9141_ $$y2025
000303495 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bDIAGNOSTICS : 2022$$d2025-01-07
000303495 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000303495 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000303495 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-08-29T10:48:13Z
000303495 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-08-29T10:48:13Z
000303495 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-08-29T10:48:13Z
000303495 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-08-29T10:48:13Z
000303495 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-07
000303495 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-07
000303495 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000303495 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000303495 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-07
000303495 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000303495 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000303495 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-07
000303495 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-07
000303495 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-07
000303495 9201_ $$0I:(DE-He78)B063-20160331$$kB063$$lB063 Krebsgenomforschung$$x0
000303495 980__ $$ajournal
000303495 980__ $$aVDB
000303495 980__ $$aI:(DE-He78)B063-20160331
000303495 980__ $$aUNRESTRICTED